Abstract: ω-3 and ω-6 Polyunsaturated fatty acids (PUFA) are the major families of PUFA that can be found as components of the human diet. After ingestion, both ω-3 and ω-6 PUFA are distributed to every cell in the body where they are involved in a myriad of physiological processes, including regulation of cardiovascular, immune, hormonal, metabolic, neuronal, and visual functions. At the cell level, these effects are mediated by changes in membrane phospholipids structure, interference with eicosanoid intracellular signaling, and regulation of gene expression. Two longchain ω-3 PUFAs, the docosahexaenoic (DHA) and eicosapentaenoic (EPA) acid, are found in fatty fish and other marine sources and might be the putative dietary components thought to modify the cardiovascular risk in subjects consuming high amounts of such food. Evidence of an inverse relationship between fatty fish intake and cardiovascular risk has, in fact, emerged in studies performed more than twenty years ago in Eskimos and has been subsequently confirmed in other ethnic groups. The benefits of ω-3 PUFA might relate principally to prevention of coronary heart disease, coronary artery restenosis after angioplasty, and sudden arrhythmic death. In this brief review, we will cover the general biochemical aspects of ω-3 PUFA, summarize the evidence relating these fatty acids with control of cardiovascular risk factors and prevention of cardiovascular events, and overview the most recent and relevant patents that are related to these issues. More specifically, we will deal with the possibility to use PUFA in association with other molecules that can potentiate their antiinflammatory and antiatherogenic effects.
INTRODUCTION
In the last decades, there has been a remarkable increase of public interest in ω-3 and ω-6 polyunsaturated fatty acids (PUFA) and their potential impact on human health. These fatty acids are not synthesized in the human body and are ingested as dietary components or oral supplements. ω-3 PUFA are found in appreciable amounts in fatty fish, such as sardines, salmon, and tuna, fish oil, walnuts, canola, and flaxseed oil and possess anti-inflammatory, anti-thrombotic, and anti-arrhythmic properties. Conversely, ω-6 PUFA are found in vegetable oils, such as corn, cottonseed, sunflower, safflower, and peanut oil and have proinflammatory and prothrombotic effects. Diets commonly eaten in the Western World contain an ω-3 to ω-6 PUFA ratio of 1:10 [1] , that is much different from the ratio of 1:1 that was peculiar of the diets consumed by our ancestors.
A low incidence of cardiovascular death among traditionally living populations such as Eskimos and Alaskan Natives was reported in seminal papers [2] [3] [4] [5] and was attributed to a lesser frequency of coronary atherosclerotic disease that could result from a high dietary intake of ω-3 PUFA from fatty fish or other fish-derived food. Many epidemiological studies have subsequently addressed the relation between the intake of ω-3 PUFA and cardiovascular disease and clinical trials have examined the effects of increased ω-3 PUFA consumption on cardiovascular events. This review will briefly cover the general biochemical aspects of ω-3 PUFA and summarize the evidence relating these fatty acids with control of cardiovascular risk factors and prevention of cardiovascular events.
GENERAL BIOCHEMICAL BACKGROUND
ω-3 PUFA are fatty acids which the first double bond is placed three carbon atoms from the methyl terminal and this structural characteristic confers to them peculiar properties as compared to other PUFA, such as the ω-6 and ω-9 PUFA. The two most important bioactive ω-3 PUFA, the eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are generated from an essential precursor molecule, the α-linolenic acid. Humans do not have the biochemical pathways required to synthesize this essential precursor of PUFA and therefore these fatty acids must necessarily be obtained form external sources such as plants, for α-linolenic acid, or marine food, for EPA and DHA ( Table 1) . In mammal species, α-linolenic acid enters cells via specific fatty acid carriers and is converted by acyl-CoA synthases in thioesters that are substrates for neutral and polar lipid synthesis in reactions of β-oxidation, elongation, and desaturation. A slow desaturation-elongation enzymatic process (rate of conversion of less than 1%) leads to formation of EPA (20 carbons) and DHA (22 carbons) that, in turn, are precursors of a family of eicosanoids that mediate the vasodilatory, anti-inflammatory, anti-thrombotic, and anti-arrhythmic effects of these molecules. The precursor of ω-6 PUFA is linoleic acid whose long-chain fatty acid derivative is arachidonic acid (20 carbons), the precursor of another family of eicosanoids that have pro-inflammatory and pro-thrombotic effects. α-linolenic and linoleic acid are competitors for the same enzymatic pathway that leads to the generation of their longer chain fatty acids whose tissue levels therefore depend very much from the amounts of the respective precursors. The ingestion of fish or fish oil provides directly ω-3 PUFA, thus avoiding the competition for enzymes in the convertion pathway.
The benefits of dietary ω-3 PUFA are attributed to their capacity to regulate specific cellular metabolic functions and gene expression [6] . ω-3 PUFA are incorporated into membrane phospholipids where they usually represent less than 10% of the total fatty acid amount. One of the targets for ω-3 PUFA effects on membrane function are lipid rafts that are cholesterol-and sphingolipid-rich regions of the outer layer of the plasma membrane [7] . These lipid rafts include proteins with multiple functions and contribute to determine the structure of many cell organelles and to modulate a number of membrane-related functions such as cellular transport, receptor function, and signal transduction. Experimental evidence indicates that lipid rafts are sensitive to changes of PUFA content via modifications occurring in both the phospholipid and protein compartments. As already noted, ω-3 PUFA affect eicosanoid pathways leading to modulation of inflammatory responses. In fact, non-esterified PUFA released from membrane phospholipids can be substrates for both cyclooxygenases (COX) and lipooxygenases (LOX) whose activity leads to generation of prostanoid and thromboxanes on one side, and leukotrienes on the other. The products of COX are modulators of the hemostatic, inflammatory, and immune response, whereas the products of LOX have control of vasomotility and vascular extravasation [8, 9] . In this context, it has been demonstrated that there is an interaction between more traditional anti-inflammatory drugs, such as aspirin, and ω-3 PUFA [10]. This interaction can be explained by the generation of specific compounds that can translate in prevention of inflammation associated with various diseases, including atherosclerosis. ω-3 PUFA have also well documented effects on gene expression and changes of mRNA levels for some lipogenic enzymes have been detected in animals fed ω-3 PUFA-enriched diets [11] . These effects appear to be mediated by activation of the peroxysome proliferator activating receptor-α (PPAR-α) that acts as a transcription factor [12] and modulates a group of genes that are involved in lipid metabolism.
USE OF ω-3 PUFA IN THE PREVENTION OF CORONARY HEART DISEASE
More than twenty years ago, epidemiological observations were reported indicating a low incidence of coronary death among native Alaskan and Greenland Eskimos who consumed a fish-rich diet [2, 3] . The same observation was subsequently extended to other ethnic groups including Japanese and Pacific Islanders [13, 14] . These observations led to the hypothesis that dietary fish consumption might decrease cardiovascular mortality. This hypothesis was tested in many prospective cohort studies that have used information obtained from food diaries and/or biologic markers to estimate dietary PUFA content. Results of these studies showed inconsistencies, since some studies confirmed the inverse relationship between dietary fish content and cardiovascular mortality rates [15] [16] [17] [18] [19] [20] while others did not [21] [22] [23] [24] [25] [26] [27] . The relationship between fish intake and cardiovascular outcome was explored also in casecontrol studies [28, 29] and randomized trials [30] reporting lower overall mortality, cardiovascular events, and sudden death, but not stroke, after consumption of dietary supplements containing EPA and DHA.
The Diet and Reinfarction Trial (DART) [30] was the first large study to examine the effects of dietary intake of ω-3 PUFA on the secondary prevention of myocardial infarction. In this 2-year follow-up study, 1,015 men who consumed two servings of fatty fish per week were compared with 1,018 men who never ate fish. The subjects who consumed fish had a 29% lower mortality but no difference in the incidence of myocardial infarction. The Lyon Diet Heart Study [31] was a randomized, secondary prevention trial that was performed in 605 patients with previous myocardial infarction. This study compared the effects of a Mediterranean-type diet (poor in total and saturated fats and rich in marine or plant derived ω-3 PUFA, vegetables and fruit, legumes, high-fiber cereals, antioxidants, minerals, vegetable proteins, and group B vitamins) with an Americantype diet (rich in cholesterol, saturated fat, and linoleic acid) on recurrences of infarction and cardiovascular death. The study was planned for a 5-year follow-up, but it was interrupted after 27 months because of significantly lower incidence of both recurrent infarction and cardiovascular death in patients consuming the Mediterranean diet. The protective effect of this diet was maintained up to 4 years after the first infarction [32] . To date, the largest randomized controlled trial on the cardiovascular effects of ω-3 PUFA is the GISSI-Prevenzione Trial [33] . This randomized trial included 11,324 patients with coronary heart disease who received either 300 mg/day of vitamin E, 850 mg/day of ω-3 PUFA, both, or neither. After a follow-up of 3.5 years, subjects taking ω-3 PUFA had 45% lower incidence of sudden death and 20% lower all-cause mortality. The U.S. Physicians Health Study demonstrated a significant inverse relationship between blood levels of ω-3 PUFA and the risk of sudden death in subjects without history of coronary heart disease [34] and another study showed that an intake of 5.5 g/month of ω-3 PUFA decreased by 50% the risk of cardiac arrest [29] . The EURAMIC study, however, showed that fish consumption did not protect against the risk of myocardial infarction [35] .
Many meta-analyses and systematic reviews [36] [37] [38] [39] [40] [41] [42] [43] ( Table 2 ) have approached the problem trying to provide a conclusive evidence on this controversial subject. A recent meta-analysis of prospective cohort studies [36] has examined a selection of 11 studies and 13 cohorts including 222,364 subjects with an average follow-up of 11.8 years. Subjects with a higher fish intake had lower coronary heart disease mortality than subjects who never consumed fish or ate fish less than once a month, with a relative risk of 0.77 for subjects who ate fish for 2 to 4 times per week. Each 20 g/day increase in fish consumption was associated with a 7% lower risk of cardiovascular death. In the same way Konig et al. [37] demonstrated a dose-response relationship between fish consumption and coronary heart disease mortality or myocardial infarction. Small amounts of dietary fish were associated with 17% reduction in coronary heart disease mortality with a further 3.9% risk reduction with each additional 100 g of fish per week. A meta-analysis of randomized clinical trials [38] has examined a selection of 14 studies testing the effects of fish oil or α-linolenic acid supplementation. This analysis concluded that fish oil containing EPA and DHA reduce significantly total mortality, coronary heart disease death, and sudden death. In a meta-analysis that included secondary prevention studies with an average follow-up of 20 months, Bucher et al . [39] demonstrated a significant reduction in fatal myocardial infarction and sudden death but could not detect any significant difference in the outcome when the analysis considered the specific sources of ω-3 PUFA. In a metaanalysis of observational studies, Whelton et al. [40] showed that eating fish reduced the relative risk of both total and fatal coronary heart disease. Similar findings were reported by Yzebe et al. [41] in their systematic review in which it was shown that daily intake of ω-3 PUFA for a mean duration of 37 months reduced fatal myocardial infarction by 24% and all cause mortality by 16%. Finally, the most recent Cochrane database review on the use of ω-3 PUFA in cardiovascular prevention [42] has concluded that there is no clear and definite evidence that these compounds decrease cardiovascular events, in particular when they are derived from natural sources.
In summary, despite important clinical studies support the role of ω-3 PUFA as protective factors toward cardiovascular disease leading the expert committees of some scientific societies to recommend their use in secondary cardiovascular prevention, some controversy on this matter still persists. Further research will be needed to better define whether, in which subjects, in which form, at which dosage, and for how long time these compounds should be used to effectively prevent the development of cardiovascular events.
MECHANISMS BY WHICH ω-3 PUFA AFFECT ATHEROSCLEROSIS
Beneficial effects of ω-3 PUFA on cardiovascular disease might result, at least in part, from specific actions on traditional and emergent cardiovascular risk factors [44] (Fig. 1) . First, ω-3 PUFA have demonstrated a dosedependent hypotensive effect in hypertensive patients. In a randomized dietary-supplementation trial on hypertensive patients, Bonaa et al. [45] demonstrated that administration of 6 g/day of ω-3 PUFA decreased systolic and diastolic blood pressure by 4.6 and 3.0 mm Hg, respectively, whereas supplementation with 6 g/day of corn oil did not affect blood pressure values. Similar results were reported in two other studies [46, 47] . A meta-analysis of 31 controlled trials showed that each 5 g/day increase of fish oil consumption decreases systolic blood pressure by 3.4 mm Hg and diastolic blood pressure by 2.0 mm Hg [48] . Also plasma triglyceride levels are decreased by ω-3 PUFA in patients with hypertriglyceridemia, an effect that could be ascribed to inhibition of the synthesis of very low density lipoproteins [49] . Studies on the effects of ω-3 PUFA on plasma lipid fractions have been reviewed showing that a dose of 4 g/day decreases plasma triglycerides by approximately 25% but leaves unaffected total cholesterol levels [50] . Recent evidence also indicates the possibility to enhance the effects of drugs commonly used for the treatment of dyslipidemias, such as statins, with the co-administration of ω-3 PUFA [51]. In a randomized placebo controlled trial conducted in patients with coronary heart disease and patients with mixed dyslipidemia who were treated with statins, ω-3 PUFA (3 g/day) decreased high sensitive C reactive protein (CRP) by 38,5%, triglycerides by 31.1% and total cholesterol by 6,3% [52] . In this study, the reduction in CRP and triglycerides was significantly greater in patients who were taking both statins and ω-3 PUFA than in those who were taking statin alone. In a double-blind study conducted in high risk patients with combined hyperlipemia, Nordoy et al. [53] demonstrated that addition of 1.68 g/day of ω-3 PUFA to atorvastatin increases the effects on HDL-cholesterol and reduce systolic blood pressure. It has been shown also that ω-3 PUFA given in addition to simvastatin in patients with combined hyperlipemia may reduce the tissue factor pathway inhibitor, a potent blocker of tissue factor mediated activation of the haemostatic cascade that plays a role in atheromasic lesions, and reduce the prothrombotic activation present in the postprandial phase [54] . In summary, there is good evidence suggesting a favorable interaction between ω-3 PUFA and statins. Further studies will be necessary to elucidate the enhanced beneficial effect of the combined therapy with ω-3 PUFA and statins in cardiovascular disease primary and secondary prevention.
Beneficial effects of ω-3 PUFA-enriched diets have been demonstrated also on some emergent cardiovascular risk factors such as lipoprotein(a) and markers of a prothrombotic state, both factors that have been shown to contribute significantly to cardiovascular outcome [55] . We have evaluated the effects of ω-3 PUFA on lipoprotein(a) and hemostatic markers in two open protocols in which hypertensive patients with high baseline levels of these markers were treated with 4 g/day of ω-3 PUFA for 1 month or with 1 g/day for 6 months [56] . In the short term, blood pressure was significantly reduced (-10 mm Hg systolic; -7 mm Hg diastolic) by the administration of the high dose ω-3 PUFA, whereas no significant changes were observed in the long term. Total and LDL cholesterol were not significantly affected by ω-3 PUFA in both studies, whereas triglycerides were decreased by 23% with the high-dose. Plasma levels of lipoprotein(a) and D-dimer were significantly decreased by both ω-3 PUFA treatments (Fig. 2) , whereas fibrinogen was significantly reduced only by the low dose. ω-3 PUFA treatment did not modify significantly levels of homocysteine, plasminogen activator inhibitor-1, and prothrombin fragment 1+2. Other studies that aimed at exploring possible effects of ω-3 PUFA on prothrombotic markers and their potential relevance for cardiovascular outcomes are limited by the sample size and the appropriateness of the design and have shown contrasting results. Despite possible contribution of ω-3 PUFA induced changes in cardiovascular risk factors, available evidence does not indicate a sufficiently large benefit to explain the overall effect of these fatty acids on cardiovascular outcomes.
Detection of intermediate or "surrogate" cardiovascular endpoints is important in the prediction of future cardiovascular "hard" endpoints, such as myocardial infarction, stroke, sudden death, and congestive heart failure. Because beneficial effects of ω-3 PUFA on these intermediate endpoints might result in better cardiovascular protection, some studies have addressed the effects of these fatty acids on such endpoints and namely on the intima media thickness (IMT) of the carotid vessels. Carotid IMT is an imaging technique that evaluates the extent of subclinical athero- sclerosis and provides important prognostic information [57] . A cross-sectional study compared the IMT in Japanese resident of a fishing village or a farming village and demonstrated that individuals with greater dietary intake of ω-3 PUFA had significantly thinner IMT than those with lower intake [58] . Similar evaluation was done in an American cohort where individuals were subdivided according to α-linolenic acid intake with evidence, in unadjusted analysis, of significantly thinner IMT in people consuming greater amounts of this fatty acid [59] . Only one randomized, controlled trial examined the effects of fish oil dietary supplementation on carotid preclinical atherosclerosis [60] . In this study, 223 patients with coronary artery disease were treated for 2 years with 1.65 g/day of ω-3 PUFA or placebo and B-mode ultrasound of carotid arteries was performed. Results showed that the degree of progression of carotid vascular disease was not significantly different in ω-3 PUFA (38%) and placebo (35%) treated individuals. Therefore, clear evidence of beneficial effects of ω-3 PUFA on IMT is lacking and so far, no studies have examined the effects of ω-3 PUFA on other intermediate cardiovascular endpoints.
Also the molecular mechanisms underlying the benefits of ω-3 PUFA on atherosclerosis have been extensively investigated in laboratory studies [61] . Long-chain ω-3 PUFA decrease adhesion molecule [62] , vascular smooth muscle cell growth factor [63] , and chemoattractant molecules [64] production and might therefore slow down the process of cell migration into the vessel wall intima that leads to atherosclerotic plaque formation. Moreover, there is some evidence suggesting that a these fatty acids might have a vascular effect by protecting endothelium through inhibition of oxidative stress, an important player in the development and progression of atherosclerotic vascular lesions [65] . In one study, cultured endothelial cells were pretreated with fatty acids and subsequently exposed to either specific cytokines or lipopolysaccharide [66] . Pretreatment with DHA blunted the endothelial response to the pro-inflammatory stimulation in terms of vascular cell adhesion molecule-1 (VCAM-1) cellular expression or release of macrophage colony stimulating factor (M-CSF). These effects were associated with decreased production of reactive oxygen species (ROS) as shown by lower depletion of cellular reduced glutathione (GSH). Other studies demonstrated that pre-incubation with DHA decreases in a dose-dependent manner the cytokine-stimulated in vitro expression of VCAM-1 by endothelial cells [67] and decreases the adhesion of monocytes to endothelial cells [68] . Similar responses were observed also when cells were pretreated with EPA, although the magnitude of the effect was smaller [68] . These cellular mechanisms may contribute to explain some of the beneficial effects of ω-3 PUFA on the risk of cardiovascular disease.
USE OF ω-3 PUFA IN THE PREVENTION OF ARRHYTHMIA
Cardiac arrhythmias are an important cause of cardiac arrest and sudden death and both epidemiological studies and clinical trials have reported beneficial effects of fatty fish or fish oil intake on this specific cardiovascular endpoint. In particular, a decrease of sudden death in individuals with high fish oil consumption has been reported in the majority of randomized, controlled trials [69] [70] [71] [72] , in prospective cohort studies [17, 26] , and case-control studies [29] . This evidence has lead to hypothesize that long-chain ω-3 PUFA might in some way suppress life-threatening cardiac arrhythmias. The hypothesis has been tested in animal models of arrhythmia [73] and prospective, randomized, placebo-controlled trials in high risk patients (severe left ventricular hypertrophy, heart failure, patients with implantable cardiac defibrillator) have been designed to address this problem [74] [75] [76] . Very preliminary results obtained in patients carrying implantable defibrillators for episodes of ventricular tachyarrhythmias demonstrated that recurrences of arrhythmia are more frequent in patients receiving fish oil supplements than those receiving a placebo [74] . A recent study, however, has shown a beneficial effect of ω-3 PUFA infusion on the induction of sustained ventricular tachycardia [77] . In this study, induction of sustained ventricular tachycardia was attempted in 10 patients who had implanted cardioverter defibrillators. Ventricular tachycardia was successfully induced in 7 of 10 patients; after infusion of ω-3 PUFA (3.8 g) tachycardia was still inducible in 2 patients, but not in the remaining 5 in whom the duration of the effective refractory period was increased. This is the first clinical study that directly demonstrates the antiarrhythmic properties of ω-3 PUFA, but is clearly limited by the sample size, absence of randomization, and absence of a control group. Another recent study performed in 160 patients after coronary artery by-pass grafting has demonstrated that administration of ω-3 PUFA at a dose of 2 g/day for a minimum of 5 days before surgical revascularization, decreases the rate of post-operative atrial fibrillation by 54.4% [78] .
Important links between ω-3 PUFA and prevention of arrhythmias have been described also in studies conducted in experimental in-vivo and in-vitro models and have been reviewed recently [73] . Experiments using a variety of ischemic animal models [79] , rats after coronary angioplasty [80] , rats with transplanted heart [81] , and studies performed with cultured cardiomyocytes [82] support the view that these long-chain fatty acids do have anti-arrhythmic properties. In fact, both feeding and infusion protocols have demonstrated in rats that the ω-3 PUFA have the ability to reduce both ventricular tachycardia and ventricular fibrillation [74] .
The potential mechanisms responsible for the observed antiarrhythmic effect of EPA and DHA have yet to be fully clarified. Ingestion of ω-3 PUFA is followed by incorporation of these fatty acids into cardiac membrane phospholipids [83] where they increase membrane fluidity [84] and thereby modulate the function of transporters, receptors, and enzymes [85, 86] . Changes of COX and phospholipase included in membrane bilayers could affect the synthesis of some eicosanoids that modify the threshold to arrhythmia induction [87] . ω-3 PUFA directly affect electrophysiological properties of cardiomyocytes by modulating conductance and prolonging the persistence in the functional inactive state of both the fast sodium [88] and slow calcium [89] current.
PATENT REVIEW COVERAGE
Several patents on cardiovascular agents and drugs have been presented in the recent years and some of these patents have relevance to the topic of this review. The most important ones deal with the possibility to reinforce the antiatherogenic, anti-inflammatory, and lipid-lowering effects of these molecules by co-administering them with other drugs with similar effects. For instance, it was unexpectedly discovered that there is an interaction between aspirin, cyclooxygenase II, and ω-3 PUFA [10]. This interaction occurs because of aspirin-driven formation of a family of at least 10 hydroxyl-compounds that have important antiinflammatory properties on different tissues, and could be potentially employed in clinical conditions associated with inflammation, such as atherosclerosis [65] . As already stated, the inflammatory actions of some metabolites of arachidonic acid such as leukotrienes and prostaglandins are well established. Because aspirin triggers the formation of epimeric forms of naturally occurring eicosanoids, the possibility that this drug might promote the formation of novel mediators from ω-3 PUFA was tested in murine models. The results of these experiments suggest a potential role of lipid-derived mediators different from those traditionally considered that might block some inflammatory pathways and stabilize endothelial cells. Another recent finding is related to the possibility to combine ω-3 PUFA with inhibitors of 5-hydroxy-5-methyl-glutaryl-CoA (HMG CoA) reductase or other cholesterol-lowering drugs [51] . This combination is endowed with a synergistic effect and appears to be particularly effective in the treatment of insulin resistance and of the pathological sequelae related to it, including atherosclerosis and cardiovascular atherothrombotic events. Also policosanols have been used in conjunction with ω-3 PUFA [90,91] for reducing total cholesterol, LDL-Cholesterol, and, more specifically, the LDL/HDL cholesterol ratio, and effect that should translate in a better prevention of cardiovascular events. With the term policosanols we indicate a family of long-chain aliphatic alcohols (triacontanol, hexacosanol, hexacontanol, etc…) that can be present as such or may be extracted and purified from a wide array of natural products that contain them, such as powders (rice bran, sugar cane, gingko biloba, etc…), oils (peanut oil, sesame oil, cod liver oil, etc…), and natural waxes (beeswax, carnauba wax, etc…). The effect of these molecules is to lower cholesterol levels by acting directly on the cholesterol synthesis pathway, thereby inhibiting the biosynthesis of cholesterol from saturated fat. This effect appears to be synergistic with the lipid-lowering actions of ω-3 PUFA and has some important potential therapeutic implications in the prevention of cardiovascular disease.
CURRENT & FUTURE DEVELOPMENTS
A large body of medical literature has evolved over the past decades evaluating the effects of ω-3 PUFA on cardiovascular disease. It is clear from the foregoing discussion that these long-chain fatty acids have been demonstrated to be effective in secondary prevention of myocardial infarction, with a particularly relevant effect on sudden death. This beneficial effect might be likely attributed to the antiarrhythmic properties of these fatty acids. Although additional research will be needed to better define precisely the role of these compounds in primary and secondary cardiovascular prevention, it would be wise to suggest oral supplementation of ω-3 PUFA in all post-MI patients and many scientific societies have now made recommendations relating the intake of fatty fish and long-chain ω-3 PUFA [92, 93] .
Epidemiological evidence and studies on traditional and new cardiovascular risk factors suggest that long-chain ω-3 PUFA might play an important role also in primary cardiovascular prevention. Although this issue needs further investigation, consumption of long-chain ω-3 PUFA should be encouraged for all individuals and especially for those at a higher risk of cardiovascular disease. Potential benefit might derive from use of these molecules in appropriate combinations with other anti-inflammatory and lipid-lowering agents.
